The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit.
Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids. The body’s gastrointestinal tract poorly absorbs cannabinoids—whether ingested in pill form or via cannabis edibles—so smoking as a means of cannabis administration has been the norm for many users in order to achieve greater effectiveness. Lexaria’s technology, however, enables the body to derive greater effect from orally administered cannabinoids without the vehicle of smoking. The company’s patented process increases bio-absorption of cannabinoids by between five- and ten-fold and, additionally, reduces onset time by about 75 percent.
In addition to poor absorption, a second hindrance exists when it comes to orally administrated cannabis, and that is an unpleasant taste that accompanies it. Companies that manufacture edible cannabis products have been forced to mask this disagreeable attribute with an overabundance of sweeteners, which adds an unhealthy element to the products and still isn’t enough to completely subdue the repellent taste. Lexaria’s technology combats this problem by effectively and thoroughly masking the unpleasant flavor of cannabis.
The company’s lipophilic enhancement technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and it’s patent-allowed for tetrahydrocannabinol (THC) and all other psychoactive cannabinoids, as well as non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and more.
Lexaria is, to date, the only company in the world to be awarded a patent for the improved oral or ingestible delivery of all cannabinoids, including pill form, beverages and edibles. The company has patents relating to its technology in both the United States and Australia and, additionally, has a portfolio of 19 national and regional patent application filings in 44 other countries.
Lexaria generates revenue by out-licensing this technology and is positioned to now out-license it at a considerable royalty rate as a partner to biopharmaceutical companies rather than a competitor. The company foresees this generating substantial new business opportunities in 2018.
For more information, visit the company’s website at www.LexariaEnergy.com
More from PsychedelicNewsWire
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…
NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…